RI
The startup develops ribonucleic acid-based gene therapies targeting cancer and degenerative neurological diseases, including Alzheimer's and hereditary conditions. By creating bio drugs that address significant medical unmet needs, the company enables healthcare providers to offer more effective treatment options for patients with these challenging diseases.
Updated 3 months ago
Funding
$64M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops ribonucleic acid-based gene therapies targeting cancer and degenerative neurological diseases, including Alzheimer's and hereditary conditions. By creating bio drugs that address significant medical unmet needs, the company enables healthcare providers to offer more effective treatment options for patients with these challenging diseases.